The abstract is read at the publisher; the summary is JClub's.
Rare loss-of-function variants in FNIP1 are linked to lower cardiometabolic disease risk in exome data from more than 1 million people, nominating FNIP1 inhibition.
- Why it matters: The study targets a gap in identifying genes that regulate the body’s energy state and influence cardiometabolic disease risk through mitochondrial energy expenditure.
- What they did: The authors performed exome sequencing on over 1 million people and tested rare variants for association with a biomarker of the body’s energy state, focusing on FNIP1.
- The result: FNIP1 loss-of-function variants were associated with reduced cardiometabolic disease risk, supporting selective FNIP1 inhibition as a potential therapeutic strategy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.